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DESCRIPTION of CASE
A 
young nurse, undertaking a working holiday in 
Australia, sees a 5-year-old Aboriginal girl while 
doing a locum in a remote coastal community of the 
Northern Territory. The young girl has been brought in by 
her grandmother because she has discharge coming from 
her eyes. From the notes, the nurse sees that the child has 
had multiple presentations for ear and skin infections but is 
otherwise well. The child’s immunisations are up to date.
The girl denies having any pain but otherwise cannot 
provide much history; neither can her grandmother, who states 
that the girl has been staying with an aunt. Upon examination 
there is a small amount of mucopurulent discharge, her 
visual acuity is normal, and the rest of the examination is 
unremarkable. A diagnosis of bacterial conjunctivitis is made, 
and the nurse is about to send the young girl home with some 
antibiotic eyedrops, when she decides to mention the girl’s 
problem to the senior clinic nurse.
Are the Diagnosis and Treatment Adequate?
The senior nurse agrees that a mucopurulent discharge 
suggests a mild bacterial infection, but is concerned about the 
possibility of a chlamydial infection. Trachoma is known to be 
hyperendemic in Central Australia; however, the prevalence 
in coastal communities is not well documented. Trachoma 
thrives in dry, dusty regions and is less common in tropical 
or coastal areas; however, the disease can thrive anywhere 
that overcrowding and poor hygiene is prevalent. When they 
examine the patient’s everted eyelids with 2.5× loupes and the 
aid of good illumination, they ﬁ  nd follicles clearly visible on 
the underside of the upper eyelid.
What Is Trachoma?
Trachoma is a keratoconjunctivitis caused by the bacterium 
Chlamydia trachomatis. It is a disease with distinct stages 
(Figure 1). These stages generally correspond to the ﬁ  ve signs 
that are assessed by the World Health Organization (WHO) 
simpliﬁ  ed grading system (Table 1); however, the stages are 
not mutually exclusive and more than one and sometimes 
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Figure 1. Natural History of Trachoma
Trachoma has a natural history consisting of three stages: active disease 
with inﬂ  ammatory follicles, scarring, and trachomatous blindness.
Table 1. Simpliﬁ  ed WHO Grading System
Grade Clinical Signs
Trachomatous inﬂ  ammation follicular 
(TF)
Five or more follicles of >0.5 mm 
on upper tarsal conjunctiva.
Trachomatous inﬂ  ammation intense 
(TI)
Inﬂ  ammatory thickening obscuring 
more than half of the normal deep tarsal 
vessels.
Trachomatous conjunctival scarring 
(TS)
The presence of easily visible scars in 
the tarsal conjunctiva.
Trachomatous trichiasis (TT) At least one eyelash rubbing on the 
eyeball or evidence of recent removal 
of in-turned eyelashes.
Corneal opacity (CO) CO blurring part of pupil margin.
Each sign is graded independently and should be included only if it is easily visible. The eyelids and cornea are 
examined ﬁ  rst for evidence of in-turned eyelashes or CO. The upper eyelid is then everted and the tarsal conjunctiva 
examined (as identiﬁ  ed in Figure 2). The conjunctiva outside this area should not be examined [1].
DOI: 10.1371/journal.pmed.0030041.t001
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all can coexist in the same eye [1]. Active inﬂ  ammation 
results from repeated or persistent infection, predominantly 
in children, and is characterised by the presence of follicles 
on the tarsal conjunctiva (undersurface of the eyelid). Such 
active inﬂ  ammation is graded as trachomatous inﬂ  ammation 
follicular (TF) and/or trachomatous inﬂ  ammation intense 
(TI) (Figure 2).
Cicatricial disease is the end result of scarring that 
occurs in individuals who suffer from severe, persistent, or 
frequent infections in childhood. Trachomatous scarring 
(TS) is recognised by the presence of easily visible white 
bands on the underside of the upper eyelid, and is more 
prevalent with increasing age (Figure 3). Severe scarring 
can result in contraction of the tarsal conjunctiva; this 
causes the lid margin to roll inwards and results in lashes 
contacting the globe. Called trachomatous trichiasis (TT), 
this is more common with increasing age; however, the age 
of onset varies according to the severity of disease within 
the community. The constant abrasions of the lashes on the 
cornea are painful and rapidly produce scarring and corneal 
opacities (CO) (Figure 4). Once the cornea has become 
opaque, visual loss is essentially irreversible.
How Do You Diagnose Trachoma?
Trachoma is generally diagnosed as a part of a screening 
program, and will not be diagnosed unless speciﬁ  cally looked 
for. It is generally asymptomatic, and only a minority of cases 
will have a mucopurulent discharge. 
In a patient presenting with a mucopurulent discharge, 
one should consider trachoma or another bacterial infection. 
The presence of follicles in the case of this Aboriginal girl 
would support the diagnosis of trachoma. However, most 
patients with follicles will be asymptomatic. (Table 2 provides 
a differential diagnosis for follicular conjunctivitis.)
If available, polymerase chain reaction (PCR) can be 
used to distinguish between these different conditions in 
the differential diagnosis (direct ﬂ  uorescence antibody 
[DFA] techniques, if available, can be substituted for PCR). 
However, these laboratory techniques are generally not of 
much practical beneﬁ  t. Not all people with active trachoma 
(TF and TI) will be positive for C. trachomatis, and both tests 
(PCR and DFA) will be positive in paratrachoma (a disease 
caused by the genital strains of C. trachomatis). Therefore, the 
diagnosis of trachoma in an individual should be made on the 
basis of clinical signs and epidemiology of the disease within 
the community. The presence of conjunctival follicles in an 
area known to have hyperendemic levels of trachoma is highly 
suggestive of C. trachomatis infection.
How Was the Patient Treated?
A swab of the young girl’s eyelid was taken and sent to 
Darwin (capital of the Northern Territory). PCR analysis 
conﬁ  rmed the diagnosis of trachoma. The girl was given 
presumptive treatment, at the initial consultation, with a 
single dose of oral azithromycin (20mg/kg), and reviewed a 
week later. At review the discharge had cleared up, but the 
follicles remained. Follicles are thought to remain for up to 
three months or so, even after infection has been cleared.
What Was the Public-Health Response?
The Centre for Disease Control in Darwin was notiﬁ  ed, and 
an action plan was implemented. An ophthalmologist was 
ﬂ  own into the community, and all children aged 1–10 years 
were screened. Each child was examined in the shade; their 
upper eyelids were everted and inspected with the aid of 2.5× 
loupes and a good light source. The presence of TF and/or 
TI was recorded. The prevalence of trachoma (TF or TI) was 
35%, with 5% having TI.
The results of the survey were reported back to the 
Centre for Disease Control, and a decision was made to 
DOI: 10.1371/journal.pmed.0030041.g002
Figure 2. Active Disease Is Characterised by Inﬂ  ammatory Follicles
Signs are considered only if they appear within the area denoted by the 
dotted line. (A) Normal conjunctiva. (B) TF. (C) TI. (D) TF and TI.
Table 2. Differential Diagnoses for Follicular Conjunctivitis
Diagnosis Distinguishing Features
Trachoma Should be suspected in an area thought to have endemic trachoma. Can be conﬁ  rmed with laboratory evidence 
of C. trachomatis infection.
Inclusion conjunctivitis Generally occurs in adults not living in trachoma-endemic areas and is related to the genital strains of C. trachomatis.
Viral conjunctivitis Is a common cause of follicles; it can be distinguished from trachoma by an acute history and the presence of a 
mucopurulent discharge.
Bacterial conjunctivitis Bacterial infection, such as Moraxella, can be a rare cause of follicle formation.
Hypersensitivity conjunctivitis Occurs following chronic exposure to drugs or eye cosmetics; a careful history is important.
Vernal conjunctivitis Is an allergic disorder; patients often have associated atopy. Symptoms include itchiness, lacrimation, photophobia, 
foreign body sensation, and burning.
Parinaud oculoglandular syndrome Is a rare ophthalmic condition that may cause follicles; it is associated with cat-scratch fever, tuberculosis, syphilis, 
lymphogranuloma venereum, and glandular fever.
DOI: 10.1371/journal.pmed.0030041.t002
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initiate a mass treatment campaign. The effective treatment 
of trachoma requires the implementation of the SAFE 
(surgery, antibiotics, facial cleanliness, and environmental 
improvements) strategy. A repeat survey was conducted 
12 months later, and the prevalence of trachoma was 
considerably decreased.
DISCUSSION
Trachoma is the leading cause of infectious blindness 
worldwide; it is endemic in 48 countries throughout the world 
and may affect as many as 84 million people [2]. Treating 
individuals with trachoma in isolation is futile because the 
disease is characterised by easy transmission and repeat 
infections. Therefore, a treated individual will be rapidly 
re-infected by those who have not been treated. At a bare 
minimum all household contacts must be treated, and ideally 
all components of the SAFE strategy should be implemented 
on a community-wide basis. The ﬁ  rst step in doing this is to 
estimate the prevalence of trachoma.
How Can You Estimate the Prevalence of Trachoma?
Instigation of a trachoma treatment program should follow 
guidelines provided by the WHO. Such a program will depend 
on the prevalence of active disease in children 1–10 years old, 
the availability of resources, and the acceptance the program 
will have in the community. In larger communities or where 
resources are scarce, it may be impractical to examine all 
children. In such cases, one of a number of survey techniques 
can be used to estimate the prevalence of trachoma [3].
Population-based prevalence surveys are the gold standard 
for estimating the level of trachoma within a community, 
and the WHO has published guidelines detailing how these 
surveys can be conducted [4]. Prevalence surveys, however, 
are expensive, time consuming, and may use resources that 
could be better spent on intervention programs. Alternate 
tools have been developed that more efﬁ  ciently estimate the 
burden of disease (these tools do not provide prevalence 
estimates).
Trachoma Rapid Assessment (TRA). This tool, developed 
by the WHO [5], attempts to quickly, cheaply, and efﬁ  ciently 
obtain the information needed to identify and prioritize 
areas for intervention programs. It uses a two-phase 
sampling technique to optimally bias the sample to detect 
people most likely to have trachoma. The ﬁ  rst phase selects 
“at-risk” communities from a region on the basis of existing 
trachoma data and known socioeconomic conditions. This 
phase was not relevant in the above case of the Aboriginal 
girl, as the identiﬁ  cation of an individual with trachoma 
immediately classiﬁ  es the community as “at risk.” Once a 
community is considered to be “at risk,” 50 children from 
the “worst areas” of that community should be examined. 
The term “worst area” relates to those houses that can be 
identiﬁ  ed as having risk factors for trachoma (Table 3). 
This technique does not provide prevalence data, but what 
it does very well is exclude the presence of trachoma as 
a public-health problem. If the children living in houses 
with the greatest risk factors for trachoma do not have the 
disease, then it can be said with some degree of certainty 
that there is no trachoma within the community.
Lot Quality Assurance Sampling (LQAS). This is another 
alternative tool for the efﬁ  cient assessment of trachoma. The 
method has long been used in manufacturing to monitor 
production quality [6]. When used as a tool for the rapid 
assessment of trachoma, the technique has been referred to as 
Acceptance Sampling Trachoma Rapid Assessment (ASTRA). 
Children are examined until either a predetermined number 
of cases with active disease is identiﬁ  ed (high prevalence) or 
a total of 50 children are sampled without the cut-off point 
being reached (low prevalence). This method has the beneﬁ  t 
DOI: 10.1371/journal.pmed.0030041.g003
Figure 3. TS Develops in Response to the Inﬂ  ammation of Active 
Disease
(A) TS: ﬁ  ne transverse lines crossing over the vessels. (B) Severe scarring.
Table 3. Risk Factors for Trachoma
Risk Factor Mechanism
Poor facial hygiene Facilitates the exchange of ocular secretions and attracts 
ﬂ  ies.
Flies The ﬂ  y Musca sorbens is known to carry C. trachomatis 
and is attracted to ocular secretions.
Overcrowding People living in overcrowded conditions, particularly if 
they share the same sleeping space, are more likely to 
transmit infectious agents to each other.
Lack of latrines Uncovered latrines are a breeding ground for ﬂ  ies.
Poor access to water Children are more likely to have unclean faces if they have 
travelled long distances to access water.
DOI: 10.1371/journal.pmed.0030041.t003
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of allowing the survey to stop as soon as it has sufﬁ  cient 
information about the likely prevalence of trachoma to allow 
an intervention strategy to be planned.
Should Clinical Examination or Laboratory Tests 
Be Used?
Clinical examination, in the form of the simpliﬁ  ed WHO 
grading system, has proven to be easily learnt by local 
health workers and has generally shown a high level of 
reproducibility [7]. It is an essential tool in the effort to 
identify populations with trachoma and to monitor the 
progress of intervention programs. However, the need for 
laboratory-based conﬁ  rmation of C. trachomatis infection, by 
the use of PCR testing, has been suggested. It is argued by 
some that clinical examination is unreliable, as it has only a 
70% correlation with PCR in high-prevalence areas, and a 
10% correlation with PCR in low-prevalence areas [8–10]. 
Moreover, after antibiotic treatment there is a more rapid 
decrease in PCR evidence of infection than there is an 
improvement of clinical signs [11,12]. These ﬁ  ndings have 
raised the concern that the use of clinical examination alone 
may result in the overtreatment of communities.
The lack of a strong correlation between clinical 
examination and PCR tests does not represent a deﬁ  ciency 
in either test; rather, it reﬂ  ects the complicated relationship 
between chlamydial infection and clinical signs of trachoma. 
Active inﬂ  ammatory trachoma can be thought of as consisting 
of three distinct stages (Figure 5). An initial incubation stage, 
during which infection can be identiﬁ  ed but clinical signs 
are absent, is followed by frank disease, where clinical signs 
and infection coexist. The recovery phase may persist for a 
considerable period of time as clinical signs slowly resolve; 
however, during this time the infectious agent is not present. 
The duration of each stage is poorly understood; however, 
it is thought that the recovery stage may persist for three 
months or longer [13]. The picture is further complicated by 
repeat episodes of re-infection or persistent infection.
Episodes of chlamydial infection are a prerequisite for 
blinding trachoma; however, lack of demonstrable infection 
does not exclude trachoma. Current research is attempting 
to develop a cheap point-of-care PCR test. However, until 
such a product is available and its cost-effectiveness proven, 
clinical examination should remain the mainstay for assessing 
the need for, and monitoring the progress of, intervention 
programs [14].
What Is the SAFE Strategy?
The SAFE strategy is being implemented on a global scale 
as part of the WHO initiative to eliminate trachoma as a 
cause of blindness by the year 2020. The strategy focuses 
on prevention; blindness from trachoma is essentially 
irreversible. Although international and national health 
bodies are generally responsible for the implementation of 
the SAFE strategy, it is community involvement and education 
about the disease at a local level that will result in elimination 
of trachoma as a blinding disease. The SAFE strategy has 
been shown to be an effective tool in reducing the blinding 
complications of trachoma and consists of four inter-related 
components [15].
Individuals with trichiasis have a greatly increased risk of 
becoming blind. These individuals need to be identiﬁ  ed and 
operated on to reduce the pain of TT and to prevent or slow 
the progression toward blindness. The WHO recommends 
the bilamellar tarsal rotation procedure [16]. The ﬁ  nding 
of trachoma in children should prompt the active search for 
trichiasis in adults, particularly those over 40 years of age.
Antibiotics are the mainstay of treatment, and the two 
recommended antibiotics are azithromycin (single dose 
of 20 mg/kg) and tetracycline eye ointment (six-week 
course). Both have been shown to be effective in eliminating 
chlamydial infection and decreasing the prevalence of 
clinical signs [17]. Azithromycin is expensive; however, a 
donation program set up by Pﬁ  zer provides the drug free of 
DOI: 10.1371/journal.pmed.0030041.g004
Figure 4. Cicatricial Disease
(A) TT scarring and contraction has pulled the lid margin in, and 
eyelashes now touch the globe. (B) CO results from the constant abrasion 
of lashes on the cornea.
DOI: 10.1371/journal.pmed.0030041.g005
Figure 5. Diagrammatic Representation of the Three Distinct Stages 
of Active Trachoma: Incubation, Frank Disease, and a Possibly 
Lengthy Recovery Period
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charge to many countries in which trachoma is endemic. If 
the prevalence of trachoma is greater than 10% in children 
1–10 years of age, then everyone in the community should be 
treated with antibiotics annually for at least three years [2]. 
Annual mass treatment should continue until the prevalence 
of trachoma is less than 5%. If available, azithromycin should 
be used, as compliance may be an issue with tetracycline.
Facial cleanliness needs to be promoted within the 
community, and adequate facilities for children to clean 
their faces need to be developed. Clean-face campaigns can 
signiﬁ  cantly reduce trachoma, particularly intense trachoma. 
Children with dirty faces are two to three times more likely to 
have trachoma [18]. Environmental changes should attempt 
to address the risk factors for trachoma: overcrowding, poor 
access to adequate latrines, ﬂ  ies, and poor access to water.
What Steps Should Be Taken to Monitor the 
Prevalence of Trachoma?
Once a treatment program has been instituted, it is 
important to monitor the effects of the program. A brief 
survey of selected areas should be conducted each year to 
ensure the performance of the program. If the prevalence 
of trachoma has risen again, then any problems in program 
implementation need to be developed and changes made. 
The institution of a trachoma intervention program will be 
different in every setting and should reﬂ  ect the resources 
available to that area and must respect the cultural 
sensitivities of the population.  
Learning Points
•  Trachoma will not be seen unless it is speciﬁ  cally looked for, 
and if it is seen it should prompt the initiation of a community-
wide public-health campaign. 
•  The magnitude of the problem, including the prevalence of 
active trachoma in children and trichiasis in adults, should be 
estimated. 
•  The individual components of the SAFE strategy should then 
be incorporated in a manner speciﬁ  c to the cultural, geo-
political, and ﬁ  nancial constraints of the community. 
•  An ongoing process to monitor the prevalence of disease and 
the mechanics of the intervention program must then be set 
up. 
•  Without the institution of a coordinated community-wide 
public-health program, the treatment of individuals with 
trachoma is a futile gesture.
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